TIM14-3 Antibody

What is TIM-3 and why is it important in immunotherapy research?

TIM-3 is a T cell immunoglobulin and mucin-domain containing-3 receptor that has gained significant attention as a promising target for cancer immunotherapy. It functions as an inhibitory immune checkpoint molecule expressed primarily on T cells, particularly on exhausted T cells that co-express PD-1. TIM-3 is also expressed by innate immune populations, including natural killer (NK) cells and dendritic cells (DCs) . The importance of TIM-3 in immunotherapy research stems from its role in mediating T cell suppression through interactions with various ligands. Blocking these interactions using anti-TIM-3 antibodies has the potential to reactivate antigen-specific T cells and enhance anti-tumor immunity, particularly in cases where patients show primary or acquired resistance to PD-1/PD-L1-targeted therapies .

What are the primary ligands of TIM-3 and how do they function in immune suppression?

TIM-3 interacts with multiple ligands that contribute to its immunosuppressive functions. The primary ligands include:

• Galectin-9 (Gal-9): Interaction with TIM-3 has been reported to mediate TIM-3 incorporation into immunological synapses and co-localize with CD45 phosphatases, dampening T cell receptor (TCR) signaling .

• Phosphatidylserine (PtdSer): Binding to TIM-3 has been shown to induce IL-10 production in T cells, contributing to immunosuppression .

• HMGB-1 (High Mobility Group Box 1): Forms complexes with TIM-3 that can be detected using specific antibodies, contributing to immune regulation .

• CEACAM-1 (Carcinoembryonic Antigen-related Cell Adhesion Molecule 1): Interacts with TIM-3 to form complexes that can be disrupted by certain anti-TIM-3 antibodies .

These ligand interactions collectively contribute to T cell exhaustion and suppression of anti-tumor immune responses, making their disruption a key strategy in cancer immunotherapy .

How can researchers determine the binding affinity of anti-TIM-3 antibodies?

Researchers can determine the binding affinity of anti-TIM-3 antibodies using several complementary methods:

• Bio-Layer Interferometry (BLI): Using systems like the ForteBio Octet, researchers can immobilize TIM-3-hFc recombinant protein onto anti-human IgG Fc capture sensors and measure association and dissociation rates of antibodies. This approach enables calculation of binding affinities (KD values) through protocols involving baseline establishment, protein loading, association of test antibodies at various concentrations, and dissociation phases .

• ELISA-Based Methods: Recombinant TIM-3 proteins can be immobilized on ELISA plates, followed by incubation with serial dilutions of anti-TIM-3 antibodies. This allows for determination of EC50 values that reflect binding affinities .

• Cell-Based Binding Assays: Using cells that stably overexpress human or cynomolgus TIM-3 (such as CHO-S-hTIM-3 cells), researchers can assess antibody binding through flow cytometry. EC50 values obtained from these assays provide a measure of binding affinity in a cellular context, which may better represent physiological conditions .

High-affinity antibodies typically show KD values in the nanomolar to picomolar range. For example, some anti-TIM-3 antibodies have demonstrated affinities ranging from 3.70 × 10−9 to 4.61 × 10−11 M .

How can researchers develop antibodies that block specific TIM-3 ligand interactions?

Developing antibodies that block specific TIM-3 ligand interactions requires a systematic approach that combines structural biology, epitope mapping, and functional screening:

• Epitope-Specific Targeting: Researchers should first identify whether they want to target linear epitopes or conformational epitopes on TIM-3. Different antibodies recognize distinct epitopes—for example, antibodies like MsT001 and MsT065 recognize linear epitopes, while MsT229 and MsT286 recognize conformational epitopes that are critical for ligand binding .

• Competitive Binding Assays: To determine whether candidate antibodies disrupt specific ligand interactions, researchers can perform competition assays. Recombinant ligand proteins (Gal-9, HMGB-1, CEACAM-1) can be immobilized on ELISA plates, followed by addition of TIM-3 protein and candidate antibodies. Reduction in complex formation indicates effective blocking .

• Functional Validation: For phosphatidylserine (PtdSer) blocking antibodies like IBI104, researchers should assess whether the antibody targets the PtdSer binding pocket while potentially inducing internalization of the whole TIM-3 molecule .

• Cross-Species Reactivity Testing: Evaluating whether the antibody binds to both human and cynomolgus TIM-3 is crucial for potential translation to pre-clinical models. Antibodies like MsT229, MsT286, and IBI104 display reactivity towards cynomolgus TIM-3, facilitating their evaluation in non-human primate models .

The development process should include screening for antibodies that maintain high sensitivity (as low as 10 pg/mL) and affinity (nanomolar to picomolar range) while specifically disrupting target ligand interactions .

What are the most effective assays for evaluating the functional activity of TIM-3 blocking antibodies?

Evaluating the functional activity of TIM-3 blocking antibodies requires a comprehensive set of in vitro and in vivo assays:

• Mixed Lymphocyte Reaction (MLR) Assay: This assay uses dendritic cells and T cells to assess the ability of anti-TIM-3 antibodies to enhance T cell activation. Measurements include cytokine production (IFN-γ, IL-2) as indicators of T cell functionality. Importantly, some antibodies like IBI104 may show limited enhancement of T cell cytokine production in vitro while demonstrating efficacy in vivo .

• NK Cell Activation Assays: Given the expression of TIM-3 on NK cells, researchers should evaluate antibody effects on NK cell activation and degranulation markers. This is particularly relevant since TIM-3 expression is highest on mature CD56dimCD16+ NK cell subsets in human PBMCs .

• T Cell Exhaustion Reversal Assays: Using TIM-3+PD-1+ T cells isolated from tumor tissues, researchers can assess the ability of antibodies to reverse the exhaustion phenotype, measuring parameters like proliferation, cytokine production, and cytotoxic activity .

• In Vivo Tumor Models: Humanized TIM-3 knock-in mouse models bearing established tumors (e.g., MC38) allow for evaluation of anti-tumor efficacy. Flow cytometry analysis of tumor-infiltrating lymphocytes can determine whether TIM-3 is predominantly expressed on PD-1+ T cells, confirming its status as a late exhaustion marker .

• Combination Therapy Assessment: Given the potential synergy between TIM-3 and PD-1 blockade, researchers should evaluate anti-TIM-3 antibodies both as monotherapy and in combination with anti-PD-1 antibodies in relevant tumor models .

These assays collectively provide a comprehensive assessment of antibody functionality beyond simple binding and blocking activities.

How should researchers design experiments to evaluate TIM-3/PD-1 combination blockade strategies?

Designing experiments to evaluate TIM-3/PD-1 combination blockade strategies requires careful consideration of several factors:

• Model Selection: Choose appropriate tumor models that express both TIM-3 and PD-1 ligands and demonstrate resistance to PD-1 monotherapy. Humanized TIM-3 knock-in (hTIM-3-KI) mouse models bearing tumors like MC38 have been successfully used to evaluate such combinations .

• Timing and Sequencing: Consider different treatment schedules:

  • Concurrent administration of both antibodies

  • Sequential administration (anti-PD-1 followed by anti-TIM-3, or vice versa)

  • Alternating schedules

• Dosing Strategy: Test multiple dose levels of each antibody individually and in combination to identify optimal dosing ratios that maximize efficacy while minimizing toxicity .

• Endpoint Measurements:

  • Tumor growth kinetics and survival

  • Immune profiling of tumor-infiltrating lymphocytes (TILs)

  • Analysis of T cell exhaustion markers on CD4+ and CD8+ T cells

  • Functional assays of T cell activity (cytokine production, proliferation)

  • Assessment of innate immune cell populations (NK cells, DCs)

• Control Groups: Include comprehensive controls:

  • Vehicle control

  • Anti-TIM-3 monotherapy

  • Anti-PD-1 monotherapy

  • Irrelevant antibody controls

• Mechanistic Analysis: Perform ex vivo studies with isolated TILs to understand the molecular mechanisms underlying observed combinatorial effects .

These experimental design considerations are informed by ongoing clinical trials investigating bispecific antibodies like LB1410, which simultaneously target PD-1 and TIM-3 and have shown better T/DC cell activity and in vivo anti-tumor efficacy compared to separate antibody combinations in preclinical studies .

What are the critical quality attributes researchers should evaluate when characterizing novel anti-TIM-3 antibodies?

When characterizing novel anti-TIM-3 antibodies, researchers should evaluate several critical quality attributes:

• Binding Specificity and Cross-Reactivity:

  • Binding to human TIM-3 (EC50, KD values)

  • Cross-reactivity with cynomolgus TIM-3 for translational studies

  • Assessment of non-specific binding to other proteins

  • Determination of epitope type (linear vs. conformational)

• Functional Activity:

  • Ability to block specific ligand interactions (Gal-9, HMGB-1, CEACAM-1, PtdSer)

  • Dose-dependent inhibition of ligand-receptor interactions

  • Enhancement of T cell and/or NK cell activation

  • Internalization of the TIM-3 receptor upon antibody binding

• Physicochemical Properties:

  • Thermal stability

  • Aggregation propensity

  • Solution behavior (solubility, viscosity)

  • Glycosylation profile (if applicable)

• Production Characteristics:

  • Expression levels in chosen production system

  • Purification efficiency

  • Stability during storage

• Immunogenicity Risk Assessment:

  • Sequence analysis for potential T-cell epitopes

  • In silico and in vitro immunogenicity assessments

Researchers should use a combination of analytical techniques including ELISA, surface plasmon resonance (SPR), bio-layer interferometry (BLI), flow cytometry, and functional cell-based assays to comprehensively characterize these attributes. For example, the sensitivity of anti-TIM-3 antibodies should reach levels as low as 10 pg/mL, and affinities should be in the nanomolar to picomolar range (3.70 × 10−9 to 4.61 × 10−11 M) for optimal performance .

What are the advantages and limitations of different antibody formats targeting TIM-3?

Different antibody formats targeting TIM-3 offer distinct advantages and limitations for research and therapeutic applications:

Each format offers specific advantages depending on research goals:

• For basic research applications where tissue penetration and modular design are important, single-domain antibodies like TIM3-R23 and TIM3-R53 offer significant advantages. These can be easily expressed in mammalian cells and bind to both recombinant and cell surface TIM-3, blocking it from binding to galectin-9 .

• For therapeutic development targeting resistance mechanisms, bispecific antibodies like LB1410 that simultaneously target PD-1 and TIM-3 may provide superior efficacy by blocking two immunosuppressive pathways concurrently .

• For applications requiring specific ligand blockade, conventional monoclonal antibodies targeting defined epitopes (like MsT229 and MsT286 for conformational epitopes) enable precise disruption of TIM-3 interactions with selected ligands .

The choice of format should be guided by the specific research question and desired functional outcome.

How can researchers assess the potential of anti-TIM-3 antibodies to overcome resistance to PD-1/PD-L1 therapy?

Researchers can employ a systematic approach to assess the potential of anti-TIM-3 antibodies to overcome resistance to PD-1/PD-L1 therapy:

• Resistance Model Establishment:

  • Generate PD-1/PD-L1 therapy-resistant tumor models through repeated exposure to anti-PD-1/PD-L1 antibodies

  • Isolate tumor cells from patients who have progressed on PD-1/PD-L1 therapy

  • Characterize the resistance mechanisms, particularly focusing on TIM-3 upregulation

• Marker Analysis:

  • Evaluate TIM-3 expression on tumor-infiltrating lymphocytes from resistant tumors

  • Assess co-expression patterns of TIM-3 with PD-1 and other exhaustion markers

  • Confirm that TIM-3 is predominantly expressed on PD-1+ T cells, supporting its role as a late exhaustion marker

• Sequential Blockade Studies:

  • Treat resistant models with anti-TIM-3 antibodies after PD-1 blockade failure

  • Monitor tumor growth, survival, and T cell functionality

  • Compare with naive tumors treated with anti-TIM-3 monotherapy

• Mechanistic Investigations:

  • Perform ex vivo functional assays with TILs from resistant tumors

  • Evaluate cytokine production, proliferation, and cytotoxicity after TIM-3 blockade

  • Conduct RNA-seq or proteomic analysis to identify molecular signatures associated with response to TIM-3 blockade in PD-1-resistant settings

• Combinatorial Approaches:

  • Test simultaneous blockade of TIM-3 and PD-1 in resistant models

  • Evaluate bispecific antibodies like LB1410 that target both pathways

  • Compare with sequential administration strategies

This approach is supported by clinical observations that TIM-3 is upregulated in anti-PD-1 therapy-resistant cancer patients, suggesting that targeting TIM-3 may provide a pathway to overcome resistance mechanisms . Evaluating both monotherapy with anti-TIM-3 antibodies and combination approaches will provide comprehensive insights into the potential of these strategies for addressing PD-1/PD-L1 therapy resistance.

What are the most promising biomarkers for predicting response to TIM-3-targeted therapies?

Several biomarkers show promise for predicting response to TIM-3-targeted therapies, based on current research findings:

• TIM-3/PD-1 Co-expression Patterns:

  • The extent of TIM-3 and PD-1 co-expression on tumor-infiltrating T cells may predict response to combination therapies

  • Flow cytometry analysis has shown that TIM-3 is predominantly expressed on a subset of PD-1+ T cells, positioning TIM-3 as a late exhaustion marker

• Ligand Expression Profiles:

  • Tumor or microenvironment expression levels of TIM-3 ligands (Gal-9, HMGB-1, CEACAM-1, PtdSer)

  • The relative abundance of different ligands may determine which anti-TIM-3 antibody (targeting specific ligand interactions) would be most effective

• Innate Immune Cell Status:

  • TIM-3 expression on NK cells, particularly on mature CD56dimCD16+ subsets

  • Activity status of dendritic cells in the tumor microenvironment

• Resistance Signatures:

  • Molecular signatures associated with acquired resistance to PD-1/PD-L1 therapy

  • Upregulation of TIM-3 following PD-1/PD-L1 therapy as a dynamic biomarker

• Epitope-Specific Considerations:

  • Different anti-TIM-3 antibodies target distinct epitopes (linear vs. conformational)

  • The availability of these epitopes in the tumor microenvironment might predict response to specific antibodies

Future research should focus on validating these biomarkers in prospective clinical trials and developing companion diagnostic assays to guide patient selection. This is particularly important as various anti-TIM-3 antibodies (MBG453, TSR-022, and Sym023) progress through early-phase clinical trials, with global approval pending for any TIM-3-targeting drug .

How might next-generation anti-TIM-3 antibodies differ from current candidates in clinical trials?

Next-generation anti-TIM-3 antibodies are likely to incorporate several advanced features that distinguish them from current clinical candidates (such as MBG453, TSR-022, and Sym023):

• Enhanced Epitope Specificity:

  • More precise targeting of specific TIM-3 epitopes that mediate interactions with individual ligands

  • Development of antibodies that can selectively block certain ligand interactions while preserving others, enabling finer modulation of immune responses

• Advanced Antibody Engineering:

  • Integration of novel antibody formats beyond conventional IgG structures

  • Incorporation of single-domain antibodies (sdAbs) or fragments with superior tumor penetration

  • Development of multispecific antibodies targeting TIM-3 alongside other checkpoints beyond just PD-1

• Receptor Internalization Properties:

  • Antibodies designed to induce greater TIM-3 receptor internalization, potentially leading to more complete pathway inhibition

  • Engineering of antibodies like IBI104 that target specific binding pockets (e.g., PtdSer binding pocket) while inducing internalization of the entire TIM-3 molecule

• Cell Type-Selective Targeting:

  • Antibodies designed to preferentially affect TIM-3 on specific immune cell populations (T cells vs. NK cells vs. DCs)

  • Tailored approaches based on the understanding that TIM-3 functions differently across various immune cell types

• Improved Pharmacokinetics:

  • Antibodies engineered for extended half-life without compromising tissue penetration

  • Optimization for specific administration routes or dosing schedules

• Reduced Immunogenicity:

  • Further humanization or de-immunization to minimize anti-drug antibody responses

  • Development approaches that reduce immunogenicity while maintaining high affinity and specificity

These advancements will be driven by deeper understanding of TIM-3 biology, structure-function relationships, and clinical experience with first-generation antibodies currently in trials. The market need for a wider variety of TIM-3 antibodies will continue to drive innovation in this space, facilitating more comprehensive investigation of TIM-3 functionality and enabling antibody selection for companion diagnostic applications .

What are the key considerations for researchers entering the field of TIM-3 antibody research?

Researchers entering the field of TIM-3 antibody research should consider several key factors to maximize the impact and relevance of their work:

• Understanding TIM-3 Biology:

  • Recognize that TIM-3 functions as an inhibitory immune checkpoint with multiple ligands (Gal-9, HMGB-1, CEACAM-1, PtdSer)

  • Appreciate that TIM-3 is primarily expressed on exhausted T cells that co-express PD-1, positioning it as a late exhaustion marker

  • Consider the role of TIM-3 on innate immune populations, including NK cells and DCs

• Antibody Development Strategy:

  • Decide whether to target linear epitopes (like MsT001, MsT065) or conformational epitopes (like MsT229, MsT286) based on the desired functional outcomes

  • Determine whether to develop conventional monoclonal antibodies, bispecific formats (like LB1410), or single-domain antibodies (like TIM3-R23, TIM3-R53)

  • Ensure antibodies have high sensitivity (10 pg/mL) and affinity (nanomolar to picomolar range)

• Preclinical Evaluation Approaches:

  • Employ a comprehensive set of assays to evaluate antibody binding, ligand blocking, and functional activity

  • Consider cross-species reactivity with cynomolgus TIM-3 to facilitate translational studies

  • Design in vivo studies using appropriate models such as humanized TIM-3 knock-in mice

• Combinatorial Strategies:

  • Explore combinations with other checkpoint inhibitors, particularly anti-PD-1/PD-L1 antibodies

  • Investigate the potential of TIM-3 blockade in overcoming resistance to established immunotherapies

  • Consider how timing and sequencing of combination therapies affect outcomes

• Translational Considerations:

  • Develop biomarker strategies to identify patients most likely to benefit from TIM-3-targeted therapies

  • Consider companion diagnostic approaches that could facilitate clinical development

  • Address manufacturing and regulatory challenges early in the development process

These considerations will help researchers navigate the complex landscape of TIM-3 antibody research and contribute meaningfully to this rapidly evolving field, which holds significant potential for enhancing cancer immunotherapy outcomes, particularly in the context of resistance to existing approaches.

How do recent findings in TIM-3 biology inform the development of next-generation immunotherapies?

Recent findings in TIM-3 biology have provided several critical insights that are directly informing the development of next-generation immunotherapies:

• TIM-3 as a Resistance Mechanism:

  • The observation that TIM-3 is upregulated in anti-PD-1 therapy-resistant cancer patients has positioned TIM-3 blockade as a strategy to overcome resistance to established immunotherapies

  • This has led to clinical trials investigating combined blockade of TIM-3 and PD-1 in patients with various cancers

• Epitope-Specific Functionality:

  • The discovery that different epitopes on TIM-3 mediate distinct ligand interactions has driven the development of antibodies targeting specific regions

  • Conformational epitopes appear particularly crucial for ligand interactions, with antibodies like MsT229 and MsT286 disrupting TIM-3's binding to Gal-9, HMGB-1, and CEACAM-1

• Cell Type-Specific Roles:

  • The recognition that TIM-3 functions differently across various immune cell populations has informed more nuanced therapeutic approaches

  • For instance, TIM-3 expression is highest on mature CD56dimCD16+ NK cell subsets in human PBMCs, suggesting potential benefits of TIM-3 monotherapy in contexts where NK cells play prominent roles

• Advanced Antibody Formats:

  • Understanding of TIM-3's cooperativity with other checkpoints has driven the development of bispecific antibodies like LB1410 that simultaneously target PD-1 and TIM-3

  • Single-domain antibodies such as TIM3-R23 and TIM3-R53 offer advantages including minimal size, excellent tumor penetration, ease of expression, and broad scope for modular structure design

• Receptor Internalization Mechanisms:

  • The finding that antibodies can induce TIM-3 receptor internalization provides an additional mechanism for pathway inhibition

  • Antibodies like IBI104 that induce internalization of the whole TIM-3 molecule while blocking specific ligand interactions represent promising approaches